Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00374322 · ClinicalTrials.gov registry record · Phase 3
Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,166
- Enrollment target
NCT00374322 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 3,166 participants.
The verdict
NCT00374322, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,166 participants
- Enrollment target
Study Summary
This study was designed to evaluate and compare the safety and efficacy of an oral dual tyrosine kinase inhibitor, lapatinib, versus placebo in women with early-stage ErbB2-overexpressing breast cancer who have completed their primary neoadjuvant or adjuvant chemotherapy and have no clinical or radiographic evidence of disease.
Interventions
- OTHER placebo
- DRUG lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,166 participants |
| Start Date | 2006-08 |
| Est. Completion | 2013-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00374322
The ClinicalTrials.gov registry entry for NCT00374322 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,166 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00374322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00374322 about?
NCT00374322 is a clinical study titled "Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer". This study was designed to evaluate and compare the safety and efficacy of an oral dual tyrosine kinase inhibitor, lapatinib, versus placebo in women with early-stage ErbB2-overexpressing breast cancer who have completed their primary neoadjuvant or adjuvant chemotherapy and have no clinical or radi...
What is the current status of trial NCT00374322?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,166 participants. The study started on 2006-08. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00374322?
The interventions under investigation include: placebo (OTHER), lapatinib (DRUG).
Who is sponsoring clinical trial NCT00374322?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.